Biotech Market News
What Drives Biotech M&A? Understanding Why Big Pharma Acquires Small Biotechs
Biotech M&A headlines are among the most consistently exciting news events in the sector — a large pharmaceutical company announces an acquisition of a smaller biotech, often at a premium of 50%, 80%, or well over 100% above the target’s prior trading price. Understanding what drives these acquisitions, how they are structured, and how to…
Qiming Leads $12M Round for Heart Pump Maker Enginprime
Enginprime Medical, a Shanghai and Hangzhou-based developer of percutaneous ventricular assist device (pVAD) technology, announced on August 17 that it has closed a $12 million Series A financing round exclusively led by Qiming Venture Partners, a large, established venture capital firm. Proceeds will fund a registration clinical trial of Enginprime’s lead device, OpusOne, in China,…
Actinium Discloses NYSE Listing Deficiency, Patent Gains
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced on August 14 a mix of intellectual property and manufacturing progress for its lead radiotherapy candidate Actimab-A, alongside a separate and more consequential disclosure: NYSE Regulation has accepted the company’s plan to regain compliance with the exchange’s continued listing standards, after confirming Actinium is not currently meeting two…
Inside Atrium Therapeutics’ Q2 2026 Earnings and New Trial
Atrium Therapeutics, Inc. (Nasdaq: RNA) reported second-quarter 2026 financial results on August 13, disclosing that the FDA has cleared its Investigational New Drug (IND) application for ATR 1072, its first precision cardiology program to enter human testing, alongside a second $15 million milestone payment earned under its cardiovascular collaboration with Bristol Myers Squibb. The San…
What Is Institutional Ownership in Biotech? Why It Matters for Retail Investors
When a well-known healthcare-focused hedge fund or a specialized biotech mutual fund takes a significant position in a clinical-stage company, retail investors often take notice — and for good reason. Institutional investors in biotech frequently employ dedicated scientific and clinical staff, including MDs and PhDs, to conduct deep diligence on clinical trial design, competitive landscape,…
Daiichi Sankyo Taps Innovent to Sell Vanflyta in China
Innovent Biologics, Inc. (HKEX: 01801) and Daiichi Sankyo Company (TSE: 4568) announced on August 9 that they have entered an exclusive agreement to commercialize Vanflyta (quizartinib) in China, an oral FLT3 inhibitor for a genetically defined, high-risk form of acute myeloid leukemia. Under the deal, Daiichi Sankyo keeps responsibility for developing, manufacturing, and supplying the…
NuGen Signs LOI to Acquire Sol-Millennium Canada
NuGen Medical Devices Inc. (TSXV: NGMD), a developer of needle-free drug-delivery systems, has signed a non-binding letter of intent to acquire Sol-Millennium Canada Inc., a Canadian distributor of medical devices and healthcare products. Under the proposed transaction, NuGen would acquire all outstanding shares of Sol-Millennium Canada from its sole shareholder, Sol-Millennium Medical HK Limited. If…
Karyopharm Plans August FDA Filing for Selinexor Combination
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration in August 2026 for selinexor in combination with ruxolitinib as a treatment for myelofibrosis. The company said it will seek accelerated approval following discussions with the FDA.…
HLS Secures Broad Private Coverage for NILEMDO Across Canada
HLS Therapeutics Inc. (TSX: HLS), a specialty pharmaceutical company focused on cardiovascular and psychiatric treatments, has expanded Canadian reimbursement access for NILEMDO, its oral cholesterol-lowering medication. The company said it has secured reimbursement agreements with Canada’s largest private payers, which it estimates represent approximately 80% of privately insured Canadians. Most patients covered by those plans…
Solventum Explores Separating Its Health Information Systems
Solventum (NYSE: SOLV) announced on August 5 that it intends to separate its Health Information Systems (HIS) business, the healthcare-software unit that handles medical coding, revenue-cycle management, and clinician-productivity software for hospitals and health systems. The company has not committed to a specific structure yet: it says it will evaluate options including a spinoff into…
